Ramatroban
Chemical compound
- None
- Rx-only (JP)
- 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
- 116649-85-5
- 123879
- 1910
- 110413
- P1ALI72U6C
- D01128
- ChEMBL361812
- DTXSID1046685
- Interactive image
- C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
InChI
- InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
- Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N
Ramatroban (INN) (also known as BAY u3405)[1] is a thromboxane receptor antagonist.[2]
It is also a DP2 receptor antagonist.[3]
It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]
It has been suggested that ramatroban, by modulating DP2 receptor, can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by SARS-Cov-2.[citation needed] Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.[6]
Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.
References
- ^ "Ramatroban (compound)". PubChem. National Center for Biotechnology Information. Retrieved 22 June 2019.
- ^ Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 347–352. doi:10.1124/jpet.102.046748. PMID 12649388. S2CID 10016709.
- ^ Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". European Journal of Clinical Investigation. 38 (9): 663–671. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
- ^ Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke. 21 (12 Suppl): IV149–IV151. PMID 2260140.
- ^ Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nihon Rinsho. Japanese Journal of Clinical Medicine (in Japanese). 54 (11): 3045–3048. PMID 8950952.
- ^ Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN (September 2020). "Pharmaco-Immunomodulatory Therapy in COVID-19". Drugs. 80 (13): 1267–1292. doi:10.1007/s40265-020-01367-z. PMC 7372203. PMID 32696108.
External links
- (in Japanese) Baynas Tablets Prescribing Information
- v
- t
- e
| Glycoprotein IIb/IIIa inhibitors |
|
|---|---|
| ADP receptor/P2Y12 inhibitors | |
| Prostaglandin analogue (PGI2) | |
| COX inhibitors | |
| Thromboxane inhibitors | |
| Phosphodiesterase inhibitors | |
| Other |
| Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
|---|---|---|---|---|---|
| Factor Xa inhibitors (with some II inhibition) |
| ||||
| Direct thrombin (IIa) inhibitors |
| ||||
| Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
